Asset
TALIGLUCERASE ALFA
Protalix BioTherapeutics Inc. (DE) Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02107846 | phase2 | completed | 2014-04-01 | 2015-12-01 | Protalix | An Open-Label, Dose Escalation Study to Evaluate the Safety and the Pharmacokinetics of Oral PRX-112 |
| NCT01747980 | phase1 | completed | 2013-03-01 | 2014-01-01 | Protalix | Safety and Pharmacokinetics of Oral PRX-112 in Gaucher Disease Patients |
FDA applications (0)
This company has no applications containing this asset.